Tirzepatide is the molecule that validated dual agonism. By engaging both the GIP and GLP-1 receptors with a single engineered peptide, it outperformed the single-receptor compounds that preceded it and reset expectations for what incretin-based design could achieve.
The Mechanism
Tirzepatide is a 39 amino acid peptide built on the GIP backbone, engineered for activity at both incretin receptors and carrying a fatty-acid moiety for week-scale half-life. Notably, its receptor balance is asymmetric — it favors GIP — and that imbalance itself became a research topic: understanding why a GIP-weighted dual agonist performs as it does has driven substantial receptor pharmacology work.
What the Published Research Shows
The clinical literature reported glycemic control and body weight results exceeding single GLP-1 agonists, with phase 3 weight reductions in the low-twenties percent range at higher doses. For the research field, the significance was conceptual: incretin receptors interact synergistically, and multi-receptor design became the default direction — leading directly to the retatrutide-class triple agonists.
Studying the Dual Agonist Class
Laboratories use tirzepatide-class compounds in receptor cross-talk studies, GIP-vs-GLP-1 contribution analyses, and as the middle arm in generational comparisons. GLP2-T is our research-class dual agonist modeled on this class — third-party tested to 99%+ purity with COA documentation, alongside its single-agonist and triple-agonist counterparts in the GLP Receptor Agonists collection.
All products referenced are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.